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Abstract
Background Physical activity has been shown to mitigate the unwanted psychological and physiological side effects of 
prostate cancer treatments, but sustainable exercise possibilities are limited.
Objective Our objective was to examine whether football in a real-world setting (i.e., local football clubs) was safe and 
feasible in practice and could improve quality of life, mitigate decline in muscle mass and bone density, and increase fat 
mass in patients with prostate cancer.
Methods In this pragmatic, multicentre, parallel randomized controlled trial, men diagnosed with prostate cancer were 
recruited from five Danish urological departments. Men (N = 214) diagnosed with prostate cancer were randomly allocated, 
using random generated lists (block size 4–8) stratified for center and androgen-deprivation therapy status, to either 1 h of 
football twice weekly in a local football club or to usual care, which was a 15- to 30-min telephone session covering their 
options for physical activity or free-of-charge rehabilitation delivered as standard in Denmark. Allocation was concealed 
from the trial investigator performing the randomization, but—given the nature of the intervention—this was not possible 
for personnel and participants. Assessments were performed at baseline, 12 weeks, and 6 months. The primary outcome was 
mean change difference in prostate cancer-specific quality of life at 12 weeks. Secondary outcomes were body composition, 
12-Item Short Form Health Survey (SF-12) physical and mental health, and safety—reported as fractures, falls, and serious 
adverse events.
Results Attrition was 1 and 3% at 12 weeks, and 5% and 5% at 6 months for the usual care and football groups, respectively. 
Prostate cancer-specific quality of life was equal between groups at 12 weeks (mean difference + 1.9 points, 95% confi-
dence interval [CI] –1.0–4.8; P = 0.20) and at 6 months (+ 0.5 points, 95% CI –2.8–3.8; P = 0.76). Fractures were equally 
distributed, with two fractures in the usual care group and one in the football group. Likewise, body composition outcomes 
were equal. Mental health improved after 6 months of football (mean difference + 2.7 points, 95% CI 0.8–4.6; P = 0.006).
Conclusions In this trial, community-based football was a feasible exercise strategy for men with prostate cancer. Football did 
not improve prostate cancer-specific quality of life but did improve mental health; the clinical significance of this is unclear.
Trial registration ClinicalTrials.gov: NCT02430792.
Abbreviations
ADT  Androgen deprivation therapy
GCP  Good Clinical Practice
FG  Football Group
UG  Usual care Group
DXA  Dual-energy X-ray Absorptiometry
QoL  Quality of Life
FACT-P  Functional Assessment of Cancer 
Therapy-Prostate
IPAQ  International Physical Activity Questionnaire
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SF-12  12-Item Short Form Health Survey
SAEs  Serious Adverse Events
MCID  Minimal clinical important difference
SD  Standard Deviation
ITT  Intention-to-treat
IQR  Interquartile range
CI  Confidence Interval
Key Points 
Systematic reviews of efficacy trials have shown that 
exercise is efficacious in improving quality of life, 
fatigue and exercise capacity. The current evidence base 
is limited regarding the evaluation of effectiveness of 
exercise strategies that can be sustained in the long term.
The results of this trial suggest that football implemented 
in local clubs for men with prostate cancer is a feasible 
exercise strategy and yields results comparable to those 
from being referred to physical activity and rehabilita-
tion.
Football was low cost, and a majority of the men contin-
ued in the football club after the study period.
1  Background
With 5.6 million men living with prostate cancer globally, 
and 1.4 million new diagnoses annually, the disease is not 
only the most frequent cancer among men but also a leading 
cause of preterm mortality in high- to middle-income coun-
tries [1, 2]. Treatment options vary according to patient and 
cancer characteristics, and most treatments induce unwanted 
psychological and/or physiological side effects [3]. In the 
case of localized disease, patients are offered curative treat-
ment, including surgery. However, when disease is recur-
rent and/or advanced at the time of diagnosis, patients are 
offered androgen-deprivation therapy (ADT), with an esti-
mated one in two patients receiving ADT at one point dur-
ing their treatment course [4]. ADT has unintended effects, 
such as weight gain due to increase in fat mass, decrease in 
bone and lean muscle mass as well as development of meta-
bolic syndrome and loss of masculinity [3, 5–7]. Some of 
these may be preventable or reversible with exercise [8, 9]. 
In addition, physical activity has been shown to reduce both 
overall and prostate cancer-specific mortality by 33% and 
35%, respectively, independent of whether patients received 
ADT [10]. Trials testing the efficacy of exercise for patients 
with prostate cancer have demonstrated positive results [8, 
9], but supporting long-term adherence and incorporating 
exercise into already existing infrastructures is challenging 
[11]. No trials fulfilling pragmatic design criteria have pre-
viously been identified in the field of exercise in men with 
prostate cancer [9]. Pragmatic trials are essential to close 
the gap between practice and science, as they are conducted 
in a real-world setting, include outcome measures that are 
relevant to patients, and are targeted at reducing resource 
use to support subsequent implementation and dissemination 
of the intervention [12]. We previously conducted a small-
scale explanatory randomized controlled trial exploring the 
physiological effects of football training and demonstrated 
improved muscle strength and greater lean body mass and 
hip bone mineral density [13, 14]. These promising findings 
prompted us to examine the real-world effectiveness of this 
intervention when delivered in pre-existing infrastructure 
(i.e., local football clubs) [15]. Sports participation in a real-
world setting is often referred to as a usable public health 
strategy for promoting physical activity [16, 17] but has 
never been assessed, to our knowledge, in a pragmatic ran-
domized controlled trial that includes a clinical population.
We therefore designed the Football Club (FC) Prostate 
Community trial to examine the effectiveness and safety of 
community-based football compared with usual care. We 
hypothesized that football would be effective in improving 
quality of life (QoL), mitigating decline in muscle mass and 
bone density, and increasing fat mass.
2  Methods
2.1  Trial Design
The FC Prostate Community trial was a pragmatic, multi-
centre, randomized controlled trial (1:1) comparing com-
munity-based football with standard (usual) care. The trial 
was performed in accordance with the Helsinki Declaration 
and Good Clinical Practice (GCP) principles. The Ethics 
Committee for the Capital Region of Denmark (H-2-2014-
099) and the Danish Data Protection Agency approved all 
of the centers involved. No changes were made during the 
conduct of the trial in relation to the original protocol [18] 
or trial registration.
2.2  Setting and Participants
Eligible participants were men diagnosed with prostate can-
cer, able to complete trial documents in Danish, and willing 
to sign informed consent. Participants were excluded if their 
treating physician proscribed participation in football or if 
they had a T score below the criterion for osteoporosis (i.e., 
T score < 2.5 for spine or hip). Patients undergoing prosta-
tectomy were not enrolled until 6 weeks after surgery.
147Football for Men with Prostate Cancer: A Randomized Controlled Trial
The first patient was enrolled in June 2015 and the last 
in February 2017. Five Danish urological departments 
recruited patients. Patients were recruited by referral when 
attending follow-up appointments at their local outpa-
tient urology clinic. Recruitment material was also avail-
able at local community centers that provide usual care 
rehabilitation.
2.3  Randomization and Masking
Patients were randomly allocated to either a football group 
(FG) or a usual care group (UG) according to a computer-
generated list of random numbers after all baseline assess-
ments were completed. A statistician not otherwise involved 
in the trial generated separate lists with a 1:1 ratio and 
varying block sizes (n = 4–8) stratified for each center and 
treatment category (receiving ADT or not) using SAS. The 
allocation was concealed from trial personnel as the statisti-
cian received a password-protected email from the trial man-
agement system  (EasyTrial®) with an upload function for 
the allocation sequence. After participants were enrolled by 
trial personnel at each hospital, the trial manager telephoned 
participants who had provided written informed consent and 
undergone all baseline measurements. Randomization was 
done using the web-based trial management system, and the 
participants were told which group they were allocated to. 
Given the nature of the intervention, neither participants nor 
coaches were blinded. Blinding was implemented for objec-
tive outcomes, so personnel performing the dual-energy 
X-ray absorptiometry (DXA) assessments had no informa-
tion on the group allocation.
2.4  Interventions
A detailed description of the intervention and procedures has 
been published in the trial protocol [18], and the develop-
ment of the educational programme for the football coaches 
has been described in a qualitative study [19]. All partici-
pants were informed during a telephone session, in which 
they were also randomized, of the guidelines for physical 
activity for cancer survivors: to be physically active > 30 min 
daily and > 10 min of vigorous activity twice a week [20].
2.4.1  Football Group
FG participants were invited to 6 months of recreational 
football for 1 h twice weekly at a local football club. A start-
up day was decided, and participants were given the local 
football coach’s contact information and told that all com-
munication on adherence, injuries, and other football matters 
was to be handled by their coach. After the 6-month period, 
participants had the opportunity to continue the interven-
tion by joining the football club on the local club’s terms, 
including paying the membership fee. Football sessions were 
scheduled to last 1 h and comprised 20 min of warm-up 
based on the Fédération Internationale de Football Associa-
tion (FIFA) 11 + program [21] with modified upper-body 
exercises and 20 min each of drills and match play. The foot-
ball coaches were recruited by the local club and underwent 
an 8- to 10-h educational program on prostate cancer treat-
ment, patient symptoms, football-specific functional tests, 
and the intervention manual. The intervention was devel-
oped to work in everyday life, as this is the natural setting 
for sports participation. The rationale also included aligning 
the intervention with traditional masculine ideals because 
the participants can be at risk of a loss of masculinity [5].
2.4.2  Usual Care Group
UG participants were told that they would not be offered 
football and received a 15- to 30-min telephone session 
covering their options for physical activity and free-of-
charge rehabilitation delivered by the municipalities, which 
is standard practice in Denmark; the rehabilitation services 
offered varies across municipalities [22]. They subsequently 
received an email containing the same information.
2.5  Outcomes
The primary outcome was mean change in total prostate can-
cer-specific QoL measured with the Functional Assessment 
of Cancer Therapy-Prostate (FACT-P) questionnaire [23] 
(Likert scoring 0–4; range 0–156; the highest score indicates 
the best QoL) assessed 12 weeks after randomization. The 
primary time point was chosen as 12 weeks post baseline, 
based on the assumption that placing the primary assessment 
of change in QoL earlier (i.e., 3 months post baseline) rather 
than later (i.e., 6 months post baseline) would limit the risk 
of response shift [24].
Objectively measured secondary outcomes assessed by 
DXA were mean change in lean body mass, fat mass, and 
hip, femoral neck, spine, and whole-body bone mineral 
density after 6 months (for information on scanners at each 
center, see the Electronic Supplementary Material [ESM]). 
Self-reported outcomes were physical activity measured 
with the short International Physical Activity Questionnaire 
(IPAQ) and general physical and mental health measured 
with the 12-Item Short Form Health Survey (SF-12). All 
participants, irrespective of allocation group, were followed-
up using the same procedures. Safety outcomes were frac-
tures and falls requiring medical assessment and any serious 
adverse events (SAEs) defined according to GCP [25]. To 
enable unbiased assessment between groups, the two safety 
outcomes were evaluated using a self-completed case report 
form administered via the web-based data capture system. 
The cost of delivering the program was calculated using the 
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actual price paid to the football clubs to cover expenses for 
purchasing equipment and reimbursement of coaches. We 
report the fraction of FG participants who continued to play 
football after 6 months; continuers were defined as attending 
more than five training sessions in the period from 6 months 
to 1 year. The coaches used a tablet-based app to submit data 
on adherence to the intervention, injuries, and fidelity in 
delivering the intervention after each session.
2.6  Statistical Analysis
2.6.1  Sample Size
The sample size calculation was based on detection of a 
minimal clinically important difference (MCID) of 6 points 
on the FACT-P questionnaire [26] at 12 weeks. Based on 
results from a pivotal exercise trial for men with prostate 
cancer [27], which reported a standard deviation (SD) of 10 
FACT-P points, an SD of 15 FACT-P points was chosen for 
the calculation as we expected the participants to be more 
heterogeneous than those in the study by Segal et al. [27]. 
With a two-sided significance level of 5% and a power of 
80%, we required a minimum of 100 participants in each 
group to detect an MCID.
2.6.2  Analysis of Primary and Secondary Outcomes
The main analyses of the primary, secondary, and safety 
outcomes were performed according to the intention-to-
treat (ITT) principle. We assessed distributions of continu-
ous variables for normality, and residuals were inspected to 
validate the models used.
If any single item was missing in FACT-P, the official 
scoring guidelines were applied, removing this item by mul-
tiplying the sum of the subscale with the number of the items 
in the subscale and then dividing by the number of items 
answered. No imputations of data from missing participants 
were performed as missing data occurred in < 3% of cases 
for the primary outcome and < 6% for any other outcomes. 
In the analysis of the primary outcome, we compared change 
score of disease-specific QoL score (total score of FACT-
P) at 12 weeks between allocation groups using analysis 
of covariance, where we included the allocation group and 
adjusted for baseline value, age, and the stratification factor 
ADT status in the model. Changes are presented as marginal 
mean differences between allocation groups with 95% con-
fidence intervals and p-values. For the secondary outcomes 
(lean body mass, fat mass, whole-body and regional bone 
measures) with two timepoints, we used the same approach 
as for the primary outcome. All figures delineate results 
from unadjusted models.
We used Fischer’s exact test to compare differences in pro-
portions of the safety outcomes (fractures, falls, and SAEs).
We performed subgroup analyses defined a priori on 
participants undergoing ADT. We also performed post hoc 
subgroup analyses stratifying participants according to 
physical activity categories proposed in the official IPAQ 
scoring protocol [28]. These analyses were performed as 
described for the ITT population. To determine the effect of 
playing football, and not just being assigned to football, we 
performed per-protocol analyses on a priori defined criteria 
of 50% adherence. To address any confounding when com-
paring all UG participants with a subgroup that cannot be 
stratified for, we adjusted for lifestyle, demographics, and 
disease prognostic risk factors known at baseline as sug-
gested by Hernán et al. [29]. For the same reason, we used 
a logistic regression incorporating the same risk factor vari-
able to analyze the comparative safety outcomes of fractures, 
falls, and admissions.
Post hoc sensitivity analyses that included disease stage, 
treatment, and Gleason score were performed to examine 
whether heterogeneity influenced effect estimates. All analy-
ses were conducted with STATA 15, version 1. The plan for 
the statistical analyses was published before any outcome 
data were collected on the trials registry site.
2.7  Patient and Public Involvement
Two patient partners were involved in the trial’s steering 
group and contributed actively in all stages of the trial, 
including seeking funding, developing research questions, 
trial conduct, and discussing trial results and the manu-
script draft. Specifically, patient partners in the steering 
group helped guide strategies to recruit patients, which 
also included help/advice from the national prostate cancer 
patient organization, which agreed to tell its members about 
the trial and to provide details about participation through 
newsletters.
The intervention manual was developed based on expert 
interviews and focus groups with patients and other stake-
holders, e.g., volunteer football coaches and urology nurses, 
as described elsewhere [19].
Published reports of trial results will be emailed to par-
ticipants and disseminated to patient advocates through the 
national prostate cancer organization and relevant scientific 
meetings and conferences.
3  Results
3.1  Study Sample
Between 15 June 2015 and 28 February 2017, we screened 
459 patients, 238 (51%) of whom were assessed for 
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eligibility, and 214 (90%) were randomized (Fig. 1). Geo-
graphic distance/travel time and poor physical condition 
were the two most prevailing reasons for declining partici-
pation in the trial. Of the 459 patients, 37 (8%) declined to 
participate, explicitly stating they had no interest in football. 
Table 1 presents the demographics and clinical characteris-
tics (n = 214).
In total, 105 patients were randomly allocated to the 
UG and 109 to the FG. Retention in the study was 98% at 
12 weeks and 95% at 6 months. For the FG, median attend-
ance from baseline to 12 weeks was 16 [interquartile ratio 
(IQR) 10] trainings (64%), and from baseline to 6 months it 
was 28 (IQR 19) trainings (59%). From baseline to 12 weeks, 
and from baseline to 6 months, 82 (75%) and 71 (65%) par-
ticipants, respectively, had an attendance to the intervention 
of ≥ 50% defining the per-protocol population.
3.2  Intervention
Fidelity to the intervention manual by football coaches 
was 3.8 (3.7–3.9) points on a 5-point Likert scale, where 
1 was non-adherence and 5 was perfect adherence to the 
intervention manual. During the trial, 616 football ses-
sions were conducted. On average, sessions lasted 58.8 
(58.4–59.3) minutes, with 20.4 (20.0–20.8) minutes spent 
on warm-up, 16.1 (15.5–16.6) minutes on drills, and 22.3 
(21.8–22.9) on match play.
3.3  Outcomes
At 12 weeks, adjusted mean change on the FACT-P score 
was 1.9 points (95% CI − 1.0–4.8; P = 0.20) higher in the FG 
than in the UG. The FACT-P adjusted mean change value 
at 6 months was 0.5 points (95% CI − 2.8–3.8; P = 0.76) 
(Fig. 2).
At both 12 weeks and 6 months, the level of self-reported 
physical activity was similar between the FG and the UG 
(P = 0.46 and 0.34) (Table 2). A significant within-group 
increase in the FG was seen from baseline to 12 weeks, with 
an increase of 115 min in the vigorous activity category. 
This increase was completely reversed at 6 months (see 
Fig. 3).
No significant differences in change between the two 
groups were seen in lean body mass, fat mass, and hip, 
238 assessed for eligibility
214 enrolled and randomized
221 declined parcipaon
• 60 due to distance / transport me
• 51 musculoskeletal problem / age
• 49 no me  / inconvenient training schedule
• 36 lack of interest in intervenon / football
• 9 disease deterioraon 
• 9 other reason
• 4 lack of energy
• 3 uncountable 
24 excluded / declined parcipaon
• 11 excluded based on T-score < 2.5 (osteoporosis)
• 2 excluded by primary physician 
• 5 no me  / lack of interest
• 3 disease deterioraon
• 1 had apoplexy
• 1 parcipated in previous study
• 1 died
109 allocated to football group105 allocated to usual care group
104 completed  12-week quesonnaires
100 completed  6-month quesonnaires
100 completed  6-month DXA scans
106 completed  12-week quesonnaires
100 completed  6-month quesonnaires
104 completed  6-month DXA scans
459 paents screened 
3 lost to follow–up
• 1 not feeling fit for intervenon
• 1 Pca disease deterioraon
• 1 sports injury and then no desire to 
parcipate 
9 / (5) lost to follow–up
• 1 (1) died, cause Pca disease
• 1 (1) not feeling fit for intervenon
• 2 (1) Pca disease deterioraon
• 1 sports injury and then no desire to 
parcipate 
• 2 (1) could not be contacted
• 2 (1) No me for doing assessments
1 lost to follow-up
• 1 declined to parcipate as not part 
of preferred group 
5 / (5) lost to follow–up
• 1 (1) died, cause Pca disease
• 1 (1) declined to parcipate as not 
part of preferred group 
• 2 (2) Pca disease deterioraon 
• 1 other disease deterioraon
• (1) lack of energy, only DXA scan
Fig. 1  Flow of participants. DXA Dual-energy X-ray absorptiometry, Pca prostate cancer, () DXA lost to follow up
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Table 1  Baseline characteristics of patients according to allocation group
Characteristic FG (n = 109) UG (n = 105) Total (n = 214)
Age (years) 67.8 ± 6.2 69.0 ± 6.2 68.4 ± 6.2
Employment status
 Paid work 26 (24) 26 (25) 52 (24)
 Unemployed 2 (2) 0 (0) 2 (1)
 Sick leave 1 (1) 2 (2) 3 (1)
 Retired 80 (73) 77 (73) 157 (73)
Education
 No education 7 (6) 5 (5) 12 (6)
 Primary education (9th/10th grade) 4 (4) 5 (5) 9 (4)
 Vocational education 33 (30) 28 (27) 61 (29)
 Secondary education (12th grade) 10 (9) 15 (14) 25 (12)
 Completed college or higher 55 (50) 52 (50) 107 (50)
Marital status
 Married or living with partner 92 (84) 93 (89) 185 (86)
 Other (single, divorced, or widowed) 17 (16) 12 (11) 29 (14)
Smoking status
 Yes 17 (16) 11 (10) 28 (13)
 No, stopped 49 (45) 51 (49) 100 (47)
 No, never 43 (39) 43 (41) 86 (40)
Alcohol consumption (drinks per week) 9.1 ± 7.2 8.5 ± 7.0 8.8 ± 7.1
Time since diagnosis, years 3.0 ± 2.7 3.8 ± 3.9 3.4 ± 3.4
Risk group
 Localized, prostatectomized 16 (15) 15 (14) 31 (14)
 Localized, not prostatectomized 27 (25) 28 (27) 55 (26)
 Locally advanced 39 (36) 42 (40) 81 (38)
 Metastatic 26 (24) 19 (18) 45 (21)
 Unknown 1 (1) 1 (1) 2 (1)
ISUP Gleason Grading
 Group 1 (Gleason score 2–6) 15 (14) 13 (12) 28 (13)
 Group 2 (Gleason score 3 + 4) 29 (27) 36 (34) 65 (30)
 Group 3 (Gleason score 4 + 3) 18 (17) 13 (12) 31 (14)
 Group 4 (Gleason score 8) 18 (17) 13 (12) 31 (14)
 Group 5 (Gleason score 9–10) 28 (26) 24 (23) 52 (24)
 Unknown 1 (1) 6 (6) 7 (3)
Number of men with bone metastasis 22 (20) 19 (18) 41 (19)
Current treatment at baseline
 No  treatmenta 46 (42) 42 (40) 88 (41)
 Anti-androgen monotherapy 15 (14) 21 (20) 36 (17)
 Castration (surgical or pharmacological) 46 (42) 41 (39) 87 (41)
 Unknown 2 (2) 1 (1) 3 (1)
Previous treatment at baseline
 Prostatectomy 27 (25) 39 (37) 66 (31)
 Radiation 37 (34) 29 (28) 66 (31)
 ADT and radiation with curative intent 21 (19) 16 (15) 37 (17)
 Chemotherapy (docetaxel) 9 (8) 10 (10) 19 (9)
 No prior or current treatment 21 (20) 24 (22) 45 (21)
Time on ADT, median days (n = 88) 512.5 (208–881) 580 (235–1089) 520 (213–982)
Number of comorbidities
 Zero 35 (32) 29 (28) 64 (30)
 One 45 (41) 46 (44) 91 (43)
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Table 1  (continued)
Characteristic FG (n = 109) UG (n = 105) Total (n = 214)
 Two 16 (15) 18 (17) 34 (16)
 Three or more 13 (12) 12 (11) 25 (12)
Baseline values on outcomes
 Prostate cancer-specific QoL (FACT-P, points) 123.7 ± 17.3 124.6 ± 16.6 124.1 ± 16.9
 Lean body mass (kg) 56.6 ± 6.3 57.5 ± 7.1 57.0 ± 6.7
 Fat mass (kg) 27.5 ± 8.0 28.3 ± 8.9 27.9 ± 8.4
 Whole-body BMC (kg) 3.1 ± 0.5 3.1 ± 0.6 3.1 ± 0.5
 Whole-body BMD (g/cm2) 1.215 ± 0.116 1.219 ± 0.125 1.217 ± 0.120
 Femoral neck BMD (g/cm2) 0.877 ± 0.155 0.877 ± 0.147 0.877 ± 0.151
 Total hip BMD (g/cm2) 1.015 ± 0.132 1.025 ± 0.138 1.020 ± 0.134
 Lumbar BMD (g/cm2) 1.188 ± 0.226 1.189 ± 0.223 1.188 ± 0.224
 Weekly self-reported PA (median MET)b 3649 (1824–6693) 4098 (2394–7732) 4046 (2010–6845)
Data are presented as mean ± standard deviation, n (%) or median (interquartile range)
ADT androgen-deprivation therapy, BMC bone mineral content, BMD bone mineral density, FACT -P Functional Assessment of Cancer Therapy-
Prostate questionnaire, FG football group, ISUP International Society of Urological Pathology, MET metabolic equivalent task, PA physical 
activity, QoL quality of life, UG usual care group
a Watchful waiting, active surveillance, previous prostatectomy, or radiation
b 102 patients in the FG and 96 patients in the UG
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Fig. 2  Mean change in outcomes, according to allocation group and time points. QoL quality of life, BMD bone mineral density
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femoral neck, spine, and whole-body bone mineral den-
sity (Table 2). For subgroup analyses prespecified for the 
ADT population, no difference from the ITT population was 
observed (see Table 2 in the ESM). Per-protocol analyses 
likewise yielded no difference from the results of the ITT 
population (see Table 4 in the ESM). To examine whether 
heterogeneity of participants affected results, sensitivity 
analyses were conducted that included disease stage, treat-
ment, and Gleason score, but they did not change the results, 
e.g., the adjusted mean change on 12-week FACT-P score 
was 2.3 points (95% CI − 0.6–5.1; P = 0.12) higher in the 
FG than in the UG.
In analyses where participants were stratified according 
to baseline physical activity level, participants who were 
categorised as being low or moderate physically active had 
a non-significant increase in lean body mass and a signifi-
cant decrease in fat mass of 0.5 kg (95% CI − 0.9 to − 0.0; 
P = 0.04). The opposite pattern was seen for highly active 
Table 2  Outcomes for the intention-to-treat population according to group allocation
Data are presented as n or mean (95% confidence interval) unless otherwise indicated
ADT androgen-deprivation therapy, BMD bone mineral density, CI confidence interval, FG football group, MET metabolic equivalent, SF-12 
12-Item Short Form Health Survey, UG usual care group
FG (n = 109) UG (n = 105) Covariance analysis, difference 
between groups
Unadjusted analyses, t test, difference 
between groups
N Mean (95% CI) N Mean (95% CI) Adjusted for ADT, age, and 
baseline score
P value Unadjusted P value
Change in prostate cancer-specific quality of life (points; higher is better)
 12 weeks 106 − 0.5 (− 2.6 to 1.5) 104 − 2.5 (− 4.6 to − 0.4) 1.9 (− 1.0 to 4.8) 0.20 2.0 (− 0.9 to 4.9) 0.18
 6 months 100 − 1.2 (− 3.6 to 1.2) 100 − 1.7 (− 4.1 to 0.6) 0.5 (− 2.8 to 3.8) 0.76 0.5 (− 2.8 to 3.9) 0.76
Change in lean body mass (kg)
 6 months 104 − 0.2 (− 0.5 to 0.1) 100 − 0.1 (− 0.4 to 0.2) − 0.1 (− 0.6 to 0.3) 0.60 − 0.1 (− 0.6 to 0.4) 0.66
Change in fat mass (kg)
 6 months 104 − 0.3 (− 0.7 to 0.2) 100 0.0 (− 0.4 to 0.4) − 0.3 (− 0.9 to 0.3) 0.28 − 0.2 (− 0.8 to 0.3) 0.42
Change in whole-body bone mineral content (g)
 6 months 104 8.9 (− 5.1 to 22.8) 100 4.3 (− 9.9 to 18.5) 3.2 (− 16.9 to 23.3) 0.75 4.5 (− 15.3 to 24.4) 0.65
Change in whole-body BMD (g/cm2)
 6 months 104 0.002 (− 0.002 to 0.007) 100 0.001 (− 0.003 to 0.006) 0.001 (− 0.006 to 0.007) 0.87 0.001 (− 0.006 to 0.007) 0.75
Femoral neck BMD (g/cm2)
 6 months 104 0.009 (0.003 to 0.016) 100 0.003 (− 0.003 to 0.009) 0.007 (− 0.002 to 0.016) 0.12 0.007 (− 0.002 to 0.016) 0.13
Change in total hip BMD (g/cm2)
 6 months 104 0.001 (− 0.006 to 0.008) 100 0.006 (− 0.002 to 0.013) − 0.005 (− 0.015 to 0.005) 0.34 − 0.004 (− 0.014 to 0.006) 0.41
Change in lumbar spine L1–L4 BMD (g/cm2)
 6 months 104 0.014 (0.003 to 0.025) 99 0.011 (0.000 to 0.022) 0.003 (− 0.013 to 0.019) 0.72 0.003 (− 0.013 to 0.018) 0.74
Change in weekly physical activity (MET minutes)
 12 weeks 96 1710 (328 to 3092) 89 638 (− 797 to 2073) 698 (1158 to 2555) 0.46 1072 (− 920 to 3064) 0.29
 6 months 90 485 (− 759 to 1729) 87 928 (− 337 to 2193) − 754 (− 2316 to 808) 0.34 − 443 (− 2217 to 1332) 0.62
Change in general physical health (SF-12)
 12 weeks 106 − 1.5 (− 2.6 to − 0.4) 104 − 1.7 (− 2.8 to − 0.6) 0.1 (− 1.4 to 1.6) 0.92 0.2 (− 1.3 to 1.8) 0.79
 6 months 100 − 2.5 (− 3.8 to − 1.2) 100 − 1.3 (− 2.6 to − 0.1) − 1.1 (− 2.9 to 0.6) 0.21 − 1.2 (− 3.0 to 0.6) 0.20
Change in general mental health (SF-12)
 12 weeks 106 0.5 (− 0.8 to 1.8) 104 − 0.8 (− 2.1 to 0.5) 1.5 (− 0.2 to 3.3) 0.08 1.3 (− 0.5 to 3.2) 0.15
 6 months 100 1.1 (− 0.4 to 2.6) 100 − 1.5 (− 2.9 to 0.0) 2.7 (0.8 to 4.6) 0.01 2.6 (0.5 to 4.7) 0.02
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Fig. 3  Weekly MET minutes, according to allocation group. MET 
metabolic Equivalent
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participants, i.e., non-significant decrease in lean body mass 
and non-significant increase in fat mass (see Fig. 4).
For physical health (SF-12) at 12 weeks, the adjusted 
mean change was 0.1 points (95% CI − 1.4–1.6; P = 0.92) 
higher in the FG than in the UG. The score at 6 months 
was 1.1 points (95% CI − 2.9–0.6; P = 0.21) lower in the 
FG than in the UG. For mental health (SF-12) at 12 weeks, 
the adjusted mean change was 1.5 points (95% CI − 0.2–3.3; 
P = 0.08) higher in the FG than in the UG. The score at 
6 months was 2.7 points (95% CI 0.8–4.6; P = 0.006) higher 
in the FG than in the UG.
3.4  Safety Outcomes, Adverse Events, and Sports 
Injuries
FG participants reported ten falls compared with six falls in 
the UG (P = 0.44). Two fractures were reported in the UG 
and one in the FG (P = 1.00). Overall, 33 hospital admis-
sions (SAEs by GCP definitions) were reported, 22 in the 
UG and 11 in the FG (P = 0.12) (see Table 1 in the ESM). 
One SAE related to the intervention was reported in the 
study and occurred due to an excoriation/scratch sustained 
when a shin guard scratched the lower leg. This later became 
infected and was not treated with the adequate antibiotic, 
resulting in a skin transplant from the thigh to the shin. The 
participant returned to football play after 8 weeks. Two 
deaths, one in each group and both due to prostate cancer, 
were reported. A total of 60 sports injuries (58 minor and 
two major) resulted in either ending a football session early 
or missing one or more football session. The most frequent 
injuries were muscle strain or sprains (n = 40), and the two 
major injuries were a partially and a fully ruptured Achilles 
tendon (see Table 6 in the ESM).
3.5  Cost and Continuation
The cost of delivering the FG intervention was Danish Krone 
(DKK) 297,500 ($US46,213 on 17 October 2018). After the 
6-month study period, 64 (59%) of the 109 participants allo-
cated to football continued the intervention and joined their 
local football club.
4  Discussion
This trial demonstrated it was possible to recruit and retain 
men with prostate cancer, with and without metastases and 
comorbidities, to community-based football. We found no 
differences in changes in prostate cancer-specific QoL or in 
body composition between the FG and the UG. However, 
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Fig. 4  Mean changes in body composition based on baseline physical activity
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at the 6-month follow-up, we found improvement in the 
exploratory outcome concerning the mental health domain 
of the SF-12 in the FG compared with the UG. The com-
parative safety outcomes demonstrated no differences in 
incidence rates of fractures, falls, and hospital admissions. 
FG participants experienced a substantial number of mostly 
minor sports injuries during the intervention. While these 
injuries did not lead to an increase in withdrawal from/termi-
nation of the intervention, they may have contributed to the 
decrease in physical activity after 12 weeks in participants 
recovering from their sports injury. A concurrent qualita-
tive study including FG participants who had sustained an 
injury indicated that participants viewed injuries as a largely 
acceptable, intrinsic feature of football that also provided 
an opportunity to embody masculine ideals (unpublished 
data). We had expected a general deterioration in QoL and 
body composition outcomes in the UG because of the natu-
ral course of the disease and the side effects of treatments 
[6, 30, 31]. However, in light of the self-reported physical 
activity data, which delineated that both groups were highly 
physically active, the finding on equality is not surprising. 
Physical activity reported at baseline also shows that our 
sample of patients with prostate cancer was highly physi-
cally active before randomization. Therefore, we performed 
sensitivity analyses separating highly physically active 
participants from those who were only low or moderately 
active. As Fig. 4 shows, different patterns were observed for 
changes in muscle mass and fat mass in the two populations, 
indicating that football might only benefit patients who are 
less physically active. This is in line with other findings in a 
recently reported exercise trial for men with prostate cancer 
[32].
A previous study by Uth et al. [13] that was optimized to 
explore the causal effects of football, i.e., comparing football 
(delivered in an ideal setting) with no football, showed an 
improvement in lean body mass of 700 g favoring football. 
The hypothesis for the current pragmatic trial was that foot-
ball would be a more potent intervention than the standard 
usual care (rehabilitation offered by local authorities), but 
the present findings did not confirm this. The discrepancy 
between the findings in the two trials might be due to dif-
ferences in the interventions in the comparison groups. It 
can be argued that control group participants perhaps are 
less likely to find physical activity interventions by them-
selves knowing that they will be offered an intervention after 
12 weeks, which was the case in the previous explanatory 
trial. In the current pragmatic trial, control group partici-
pants knew they would not be offered the football inter-
vention for a whole year. With regard to attendance and 
workload during football training, our data show results 
similar to those from the previous explanatory trial [33]. In 
the explanatory trial, where participants were coached by a 
professional sport physiologist, participants ran 905 ± SD 
297 m at speeds > 6 km/h and 2646 ± 705 m per session. In 
comparison, activity profiles sampled conveniently (n = 67) 
in the current pragmatic trial with local coaches showed that 
participants ran 973 ± 582 at running speeds > 6 km/h and a 
total of 2684 ± 918 m per session.
Several recently published systematic reviews on exer-
cise for men with prostate cancer have outlined that exercise 
improves QoL, fatigue, fitness, and functional outcomes [8, 
9, 34–36]. The studies generally focused on delivering exer-
cise in healthcare clinics. Recent studies have focused on 
safety, feasibility, and initial efficacy of physical exercise 
for patients with prostate cancer with skeletal metastases 
[37, 38]. Even though the current trial was not designed 
to explore the issue of safety for this subpopulation, we 
enrolled 41 patients with skeletal metastases. We tested 
whether men with metastases had fewer training sessions 
than those without metastases and found this not to be the 
case (data not shown). This suggests that future studies pow-
ered and designed to test whether vigorous exercise is safe 
for men with bone metastases are possible.
We conducted a qualitative study, which indicated that 
men with prostate cancer undergoing ADT viewed football 
as an opportunity to take back control and responsibility 
for their own health without being in the role of patient, 
and that football enabled peer-to-peer caring behavior in a 
male setting [39]. This can be interpreted as being in align-
ment with the improvement in mental health, which at the 
same time should be interpreted with caution, as this was 
an exploratory outcome chosen primarily for the purpose 
of conducting health economic analysis. Only 4% (data not 
shown) of participants played football before entering the 
study and 57% joined their local club and continued play 
after the study period.
The financial cost of delivering the football intervention 
was DKK2600 ($US404) per participant. In comparison, a 
report by the Danish National Centre for Social Research 
estimated the average cost of rehabilitation delivered by two 
different local authorities in Denmark to be DKK29,211 
($US4538) for 12.9 weeks of rehabilitation and DKK32,478 
($US5045) for 10.8 weeks per patient [40].
Collectively, this information supports the suggestion 
that sports participation is appealing and feasible as a public 
health strategy for clinical populations [16, 17].
The trial had various methodological strengths. First, 
assessments and DXA scans were performed by blinded 
assessors, and the self-reported questionnaires were auto-
mated via a web-based system, helping to minimize errors 
and limit the influence of trial staff on participants. Safety 
outcomes and SAEs were followed-up using the same 
method for all participants; at the same time, all injuries 
related to the intervention were collected prospectively. Sec-
ond, attrition bias was minimal as retention was 98 and 95%. 
155Football for Men with Prostate Cancer: A Randomized Controlled Trial
Third, the trial followed GCP principles, ensuring homoge-
neity between study sites.
Limitations include the obvious inability to blind par-
ticipants and coaches delivering the intervention. While this 
can induce bias on the self-reported outcomes, these meas-
ures yielded similar results to the objectively measured and 
assessor-blinded outcomes. When claiming equality between 
groups, several methodological features need to be consid-
ered: the sample size should be large because CIs should not 
exceed a certain marginal size, which preferably should have 
been set in advance, though this was not the case in this trial. 
In the interpretation of the trial results, we used the delta val-
ues stated a priori from our original sample size calculations, 
i.e., the MCID of 6 points for FACT-P [26] and a 700 g 
change in lean body mass from Uth et al. [13]. We found 
that 95% CIs did not exceed these margins. We observed 
lesser variations than expected in outcomes, which is why 
the trial had more power than anticipated. Last, a trial can 
wrongfully claim equivalence in safety if a sufficient propor-
tion of participants are lost to follow-up or if participants not 
receiving the intervention are diluting the estimates of the 
ITT analysis. This trial had a negligible withdrawal rate, and 
we performed per-protocol analysis as sensitivity analyses to 
address any dilution (see the ESM). In regard to the per-pro-
tocol population defined as adherence of 50%, a limitation is 
that only two sessions were scheduled per week and higher 
attendance could have incurred possible benefits, especially 
for the physiological outcomes. Regarding generalizability, 
the pragmatic multicentre design is valuable as it ensures 
that the estimated results reflect a real-world implementa-
tion of community-based football compared with relevant 
alternatives. One issue concerning the pragmatic design is 
whether the heterogeneity of participants potentially reduced 
the ability to infer validly on the measured outcomes. For 
this reason, we performed post hoc sensitivity analyses with 
any baseline covariate that might be a prognostic factor to 
test whether this would change the results. However, it only 
changed the results minimally and did not lead to any differ-
ence in interpretations. We also report subgroup analyses for 
the ADT population, which, as the width of CIs shows, was 
adequately powered with a total of 87 participants.
5  Conclusion
In the current trial, football implemented in local foot-
ball clubs under the supervision of lay coaches was a 
feasible exercise strategy for patients with prostate can-
cer. It improved the exploratory outcome mental health 
but offered no additional benefits with respect to prostate 
cancer-specific QoL or body composition after 6 months 
compared with encouragement/referral to physical activity 
and rehabilitation. As the risk of sports injuries seems to 
be an embedded aspect of participating in football, patients 
wishing to partake must accept this. Future research on 
sport, exercise, and physical activity should be conducted 
in real-world structures to enable low-cost upscaling.
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